Vaxcyte (NASDAQ:PCVX) Posts Earnings Results

Vaxcyte (NASDAQ:PCVX) announced its earnings results on Wednesday. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09, FiscalAI reports. During the same period last year, the business earned ($1.22) earnings per share.

Vaxcyte Stock Up 4.7%

Shares of NASDAQ:PCVX traded up $2.62 during trading on Thursday, hitting $58.54. 737,457 shares of the company traded hands, compared to its average volume of 1,424,531. The stock has a market capitalization of $8.45 billion, a price-to-earnings ratio of -8.47 and a beta of 1.23. The business’s fifty day moving average is $53.56 and its 200-day moving average is $55.10. Vaxcyte has a one year low of $29.08 and a one year high of $65.00.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PCVX. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Vaxcyte presently has an average rating of “Hold” and an average price target of $86.00.

Insider Buying and Selling

In related news, insider Harpreet S. Dhaliwal sold 17,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the transaction, the insider directly owned 76,756 shares in the company, valued at $4,221,580. This represents a 18.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 133,215 shares in the company, valued at $7,413,414.75. This represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 120,646 shares of company stock worth $6,570,810. Company insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors have recently modified their holdings of the company. Caligan Partners LP acquired a new position in Vaxcyte during the 4th quarter valued at about $78,660,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Vaxcyte by 418.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock worth $79,592,000 after acquiring an additional 1,392,000 shares during the period. Wellington Management Group LLP lifted its stake in shares of Vaxcyte by 18.5% in the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock worth $275,286,000 after acquiring an additional 933,539 shares during the period. Deep Track Capital LP lifted its stake in shares of Vaxcyte by 39.5% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $108,060,000 after acquiring an additional 850,000 shares during the period. Finally, Qube Research & Technologies Ltd bought a new position in shares of Vaxcyte in the second quarter valued at approximately $26,318,000. Institutional investors own 96.78% of the company’s stock.

Key Headlines Impacting Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter EPS of -$1.97, better than the consensus estimate of -$2.06. However, the loss was wider than the -$1.22 reported in the year-ago quarter, underscoring that the company remains unprofitable. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial of VAX-31 are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 Phase 3 trials are expected in the first half of 2027, potentially providing important evidence for the company’s lead pneumococcal vaccine program. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong cash position supports development: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The liquidity gives the company substantial resources to fund late-stage VAX-31 trials and its newly initiated VAX-A1 Phase 1 study.
• Neutral Sentiment: Early-stage pipeline expansion: Vaxcyte initiated a Phase 1 study of VAX-A1 for the prevention of Group A Streptococcus disease, with topline data expected in the second half of 2027. This expands the pipeline but is still several years from potentially affecting revenue.
• Negative Sentiment: Executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Because the transactions were executed under pre-arranged Rule 10b5-1 trading plans, they may be less indicative of current management sentiment, though the sales could still weigh modestly on investor confidence. Vaxcyte insider selling report

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.